Close this search box.
Close this search box.

Acorai: Transforming Heart Failure Management with Non-Invasive Heart Pressure Monitoring

Image Credits: Acorai
By: Headliners News / April 9, 2024

Meet Acorai, a Swedish medical device startup who has garnered attention with its oversubscribed seed funding round, raising over $4.5 million not too long ago. Specializing in non-invasive heart pressure monitoring, Acorai combines proprietary sensing hardware and machine learning software to provide a tool for clinicians. The startup’s Heart Monitor device, a handheld unit roughly the size of a smartphone, utilizes seismic sensors, acoustic sensors, visual sensors, and ECG sensors to estimate intracardiac pressure directly through the patient’s skin.

Patients with heart failure often require invasive procedures to measure pressure inside the heart chambers. Acorai’s solution aims to make this process more accessible and less invasive. The startup’s patented sensing system picks up various signals, including vibrations, sounds, visual blood flow, and electrical activity, to estimate intracardiac pressure without the need for more invasive procedures.

The Heart Monitor device targets suspected or confirmed heart failure patients, a population estimated at around 60 million worldwide. Acorai aims to address the gap where only approximately 10% of heart failure patients undergo invasive procedures, allowing clinicians to follow patients temporarily, measuring pressure multiple times per day and observing trends over time.

The device integrates with proprietary machine learning algorithms, providing clinicians with a direct estimate of pressure rather than an AI-generated risk index. Acorai’s pilot study in Sweden demonstrated promising results, with accuracy levels comparable to implantable sensors on the market.

Acorai is positioning its product as a clinician-support tool rather than a diagnostic medical device, emphasizing that trained medical professionals would be responsible for patient care decisions. The startup’s go-to-market strategy focuses on the U.S. healthcare system, where it aims to launch the device in hospitals in the second half of 2025, pending regulatory clearance.

The recent seed funding round, led by Solardis Health Ventures, will primarily be allocated to clinical studies as Acorai works towards FDA approval for clinical use. The startup plans to raise a Series A later this year to navigate global regulatory pathways and support initial commercialization efforts, primarily in the U.S. Notable investors include Mayo Clinic, Cedars-Sinai, Bayer, and various angel investors and VCs.

What do you think?

2 People voted this article. 2 Upvotes - 0 Downvotes.
Please Share This